Therapeutic potential of ketamine in depressive disorders

Authors

DOI:

https://doi.org/10.33448/rsd-v12i2.40153

Keywords:

Ketamine; Depressive Disorder, Major; Depressive disorder treatment-resistant.

Abstract

Introduction: One third of individuals living with major depressive disorder do not respond to antidepressant-based treatment. Suicidal ideation is a frequently present aggravating factor that is possibly lethal if not understood. The difficult control of the wide symptomatology related to depression in certain patients demonstrates the need for new and efficient therapeutic strategies. It was verified that ketamine presents antidepressant results when manipulated in subanesthetic doses. This research aims to verify the antidepressant potential of ketamine on major depressive disorder and resistant depressive disorder in scientific productions published between 2017 and 2022. Methodology: This is an integrative literature review. After searching the Virtual Health Library database, 100 publications were found, but only 12 articles met the inclusion criteria. Results and discussion: The NDMA receptor blockade promoted by ketamine is indicated as the cause of the rapid attenuation of depressive symptoms, which restores the synaptic dynamics of some maladjusted glutamatergic pathways in depressive disorders, restores the neural activity of important circuits related to stress, resilience and mood regulation, essentially modulating the emotional cognitive control function. In addition, it acts by regulating dysfunctional immunoinflammatory reactions involved in the pathophysiology of depression. Conclusion: The use of ketamine for the treatment of major depressive disorder and resistant depressive disorder has expressive and relevant results that make it a strong candidate to compose the arsenal adopted by international guidelines.

References

American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). American Psychiatric Publishing.

Campos, C. J. G. (2004). Método de análise de conteúdo: ferramenta para a análise de dados qualitativos no campo da saúde. Rev Bras Enferm, 57(5), 611-614.

Canuso, C. M. (2018). Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Am J Psychiatr, 175(7).

Ekstrand, J. (2022). Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial. International Journal of Neuropsychopharmacology, 25(5), 339-349.

Grunebaum, M. F. (2018). Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. Am J Psychiatry, 4(175), 327-335.

Hull, T. D. (2022). At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. Journal of Affective Disorders, (314), 56-67.

Kamp, J. (2020). Pharmacokinetics of ketamine and its major metabolites norketamine, hydroxynorketamine, and dehydronorketamine: a model-based analysis. British Journal of Anaesthesia, 125(5), 750-761.

Kruse, J. L. (2021). Depression treatment response to ketamine: sex-specific role of interleukin-8, but not other inflammatory markers. Translational Psychiatry, 167(11).

Mendes, K. D. S. et al (2008). Revisão Integrativa: Método de pesquisa para a incorporação de evidência na saúde e na enfermagem. Texto Contexto Enferm, 17(4), 758-64.

Milak, M. S. (2020). Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression A Randomized Clinical Trial. Psychiatry, 3(8).

Mkrtchian, A. (2021). Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals. Molecular Psychiatry, (26). https://doi.org/10.1038/s41380-020-00878-1

Phillips, J. L. (2019). Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology, (45), 606?612.

Phillips, J. L. P., & Norris, S. (2019). Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. Am J Psychiatry, 5(176).

Popova, V. (2019). Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry, 6(176), 428-438.

Rivas-Grajales, A. M. (2021). Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. International Journal of Neuropsychopharmacology, 24(5), 383?391.

Rother, E. T. (2007). Revisão sistemática X revisão narrativa. Acta paulista de enfermagem, 20(2), 5-6.

Sampaio, R. F., & Mancini, M. C. (2007). Systematic review studies: a guide for careful synthesis of the scientific evidence. Brazilian Journal of Physical Therapy, 11(1), 83-89.

Souza, M. T. d. (2010). Integrative review: what is it? How to do it? Einstein, 8(1). https://doi.org/10.1590/S1679-45082010RW1134

Teixeira, F. M. et al (2013). Metodologias de pesquisa no ensino de ciências na América Latina. Ciência & Educação, 19(1), 15–33.

Vancappel, A. (2021). Cognitive impairments in treatment-resistant depression: Results from the French cohort of outpatients (FACE-DR). Journal of Affective Disorders Reports, (6). https://doi.org/10.1016/j.jadr.2021.100272

Yrondi, A. (2018). Electroconvulsive therapy, depression, the immune system and inflammation: A systematic review. Brain Stimulation, 11(1). https://doi.org/10.1016/j.brs.2017.10.013

Zhou, Y. (2021). Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine. Journal of Neuroinflammation, 18(2000). https://doi.org/10.1186/s12974-021-02245-5

Downloads

Published

01/02/2023

How to Cite

MENDES, L. F. da S. .; BEZERRA, C. de S. .; PIAUILINO, B. C. N. .; SOUSA, L. L. de .; LEAL, A. K. M. P. .; MOURA, P. R. de S. e S. .; SILVA, L. S. A. da .; NORONHA, M. Y. de C. .; MENEZES, A. G. V. A. . Therapeutic potential of ketamine in depressive disorders. Research, Society and Development, [S. l.], v. 12, n. 2, p. e15812240153, 2023. DOI: 10.33448/rsd-v12i2.40153. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/40153. Acesso em: 16 apr. 2024.

Issue

Vol. 12 No. 2

Section

Health Sciences

License

Copyright (c) 2023 Lucas Ferrari da Silva Mendes; Camila de Sá Bezerra; Bárbara Cândida Nogueira Piauilino; Lourivan Leal de Sousa; Anne Kaline Marques Portela Leal; Paulo Ricardo de Sousa e Silva Moura; Lucas Solano Araújo da Silva; Maria Yasmin de Carvalho Noronha; Antônio Gleysson Vieira Abreu Menezes

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.